Ridgewood NJ, more than 2 years after Johnson & Johnson’s vaccine was first approved by the FDA, it is now no longer available anywhere in the US, according to the CDC. Over 31.5 million doses of the J&J vaccine have been distributed across the country since March 2021 — 19 million of which made it into Americans’ arms, CNN reported.
Summit NJ, Johnson & Johnson spun off its Kenvue consumer brands division on Thursday, raising the most cash from an initial public offering (IPO) in more than a year. Johnson & Johnson said it sold 172.8 million shares(opens in new tab) at $22 a pop in Kenvue, giving the company whose brands include Band-Aid, Tylenol and Listerine a valuation of roughly $40 billion.
New Brunswick NJ, on Jan. 10, attorneys for Children’s Health Defense (CHD) filed an appeal in the United States Court of Appeals for the Third Circuit challenging the New Jersey District Court judge’s Sep. 22, 2022 dismissal of CHD’s Aug. 16, 2021 lawsuit against Rutgers and university officials for their COVID-19 vaccine requirement for students to attend classes, whether in person or remotely. The mandate that began at the start of the 2021 Fall semester now requires full vaccination and boosters for students, faculty and staff.
Founded in 1886 in New Brunswick, New Jersey, Johnson & Johnson has become the largest healthcare corporation in the world over the decades, with 250 subsidiary companies operating in 60 countries. However, the company has been the subject of controversy many times. For instance, while Johnson & Johnson had known that the talc in its famous baby powder was contaminated with asbestos since the ‘70s, the company decided to keep this a secret from consumers. Consequently, thousands of people came to struggle with ovarian cancer and mesothelioma, a sporadic and aggressive cancer of the lungs, several decades later. Johnson & Johnson had to pay millions of dollars to the victims in over 40,000 cases.
Egg Harbor NJ, Governor Phil Murphy and Acting Attorney General Matt Platkin today announced that New Jersey is set to receive $641 million from settlements with Johnson & Johnson, which manufactured opioids, and the country’s three largest pharmaceutical distributors – McKesson, Cardinal Health, and AmerisourceBergen. The $641 million in settlement funds will be paid through 2038 and will fund state and local programs focused on treatment, prevention, and other strategies to combat the opioid epidemic in the state.
New Brunswick NJ, New Jersey based Johnson & Johnson said on Friday that it is planning to break up into two separate companies, splitting off its consumer health division that sells Band-Aids and Baby Powder from its large pharmaceuticals unit.
New Brunswick NJ, Johnson & Johnson announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.
In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization.
New Brunswick NJ, according to Johns Hopkins Center for Health Security industry competitors Johnson & Johnson (J&J) and Merck & Co. announced that they will work together to manufacture the J&J-Janssen SARS-CoV-2 vaccine. Currently, there are only approximately 4 million doses available for distribution. J&J was supposed to produce 12 million doses by the end of February, but it fell behind schedule.
New Brunswick NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.
New Brunswick NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial.
New Brunswick NJ, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, that Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, paving the way for its approval for emergency use (EUA) .
NEW BRUNSWICK NJ, Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19.
New Brunswick NJ, Interim Phase 1/2a data were published today in the New England Journal of Medicinedemonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.
New Brunswick NJ, earlier this week, New Jersey based Johnson & Johnson (J&J) reportedly announced that is reducing the size of its ongoing US SARS-CoV-2 vaccine clinical trial. The ongoing COVID-19 surge in the US actually benefits the trial by increasing the rate that participants are exposed and infected, meaning that the trial can meet its designated endpoint (e.g., specific number of cases) with fewer participants. In a recent press conference Dr. Moncef Slaoui, co-lead of Operation Warp Speed, emphasized that, while Pfizer and Moderna are moving closer to receiving Emergency Use Authorization, the J&J and AstraZeneca candidates are critical to the US government’s goal of vaccinating all Americans by summer 2021. J&J temporarily paused the Phase 3 clinical trials earlier this year in order to investigate an adverse event in the trial group, but it resumed the trial on October, 23.
New Brunswick NJ, Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s phase 3 clinical research study to evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate.